LMGF(SZ:002734)2023-10-27 16:00Financial Performance - The company's revenue for Q3 2023 was approximately ¥1.09 billion, representing a decrease of 11.47% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of approximately ¥35.54 million, a decline of 228.38% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of approximately ¥41.90 million, down 355.08% from the previous year[5]. - The basic earnings per share for the period was -¥0.10, a decrease of 242.86% compared to the same period last year[5]. - Total operating revenue for Q3 2023 was CNY 3,397,845,982.07, a decrease of 16.0% compared to CNY 4,042,093,577.37 in the same period last year[17]. - Net profit for Q3 2023 was CNY 21,933,381.55, a significant decline from CNY 184,918,304.21 in Q3 2022, representing a decrease of 88.1%[18]. - Total comprehensive income for the third quarter was CNY 22,722,457.77, a decrease from CNY 187,268,818.12 in the previous year[19]. - Basic earnings per share for the third quarter was CNY 0.06, compared to CNY 0.48 in the same period last year[19]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥7.07 billion, an increase of 0.17% from the end of the previous year[5]. - The company's total assets as of Q3 2023 amounted to CNY 7,068,094,668.97, slightly up from CNY 7,056,123,806.23 at the end of the previous quarter[16]. - Current liabilities totaled CNY 2,646,729,035.20, a decrease of 8.6% from CNY 2,894,194,608.77 in the previous year[16]. - The total liabilities as of Q3 2023 were CNY 4,294,408,391.38, compared to CNY 4,215,992,118.92 in the previous year, reflecting a slight increase of 1.9%[16]. - Long-term borrowings increased to CNY 679,350,000.00, up from CNY 369,880,000.00, indicating a rise of 83.5% year-on-year[16]. - The equity attributable to shareholders of the parent company decreased to CNY 2,732,881,417.62 from CNY 2,798,466,418.03, a decline of 2.3% year-on-year[16]. Cash Flow - The company's cash flow from operating activities for the year-to-date was approximately ¥53.76 million, down 85.91% compared to the same period last year[5]. - Net cash flow from operating activities was CNY 53,763,644.87, significantly down from CNY 381,653,409.53 in the previous year[21]. - Cash inflow from operating activities totaled CNY 2,352,622,778.34, down 26% from CNY 3,182,234,629.72 year-on-year[21]. - Cash outflow from operating activities was CNY 2,298,859,133.47, a decrease from CNY 2,800,581,220.19 in the previous year[21]. - Net cash flow from investing activities was CNY -166,552,630.36, compared to CNY -1,053,140,929.92 in the previous year[21]. - Cash inflow from investing activities was CNY 14,719,701.59, down from CNY 512,903,992.26 year-on-year[21]. - Cash outflow from investing activities totaled CNY 181,272,331.95, a decrease from CNY 1,566,044,922.18 in the previous year[21]. - Net cash flow from financing activities was CNY 160,137,280.48, down from CNY 561,099,301.25 in the previous year[21]. - The ending balance of cash and cash equivalents was CNY 562,135,701.46, compared to CNY 597,984,823.15 at the end of the previous year[21]. Investments and Strategic Agreements - The company signed a strategic cooperation agreement with Jiangsu Agricultural Reclamation Biochemical Co., Ltd. on July 13, 2023, to enhance technological capabilities in pesticide raw material development[12]. - A strategic cooperation agreement was also signed with Jiangxi Jinhui Lithium Battery Materials Co., Ltd. on August 4, 2023, focusing on procurement, technology, and capital operations in the new energy materials sector[12]. - The company’s subsidiary, Hebei Shuangji Chemical Co., Ltd., received approval for a project to produce 600 tons of cyclic sulfonic acid annually, enhancing production capacity[12]. - The company’s subsidiary, Hebei Weiyuan Biological Chemical Co., Ltd., received environmental approval for a project to upgrade production of 1,000 tons of glyphosate and 10,000 tons of refined glyphosate annually[12]. Financial Management - The company experienced a significant increase in financial expenses, up 452.92%, primarily due to increased interest expenses on bank loans[9]. - The company reported a significant increase in financial expenses, which rose to CNY 64,677,377.66 from CNY 11,697,349.91, marking a rise of 450.5%[18]. - The company's investment income decreased by 211.08%, attributed to changes in the profitability of associated companies[9]. - Inventory decreased by 33.81%, mainly due to product sales during the reporting period[9]. - The company reported a 42.16% increase in trading financial assets, as subsidiaries increased investments in financial products using idle funds[9]. - The company’s trading financial assets increased to ¥10,002,808.22 from ¥7,036,393.41, reflecting improved investment strategies[13]. - The company’s accounts receivable financing decreased to ¥16,021,507.32 from ¥80,653,903.40, indicating a shift in financing strategy[13]. - The company’s prepayments slightly decreased to ¥86,484,703.81 from ¥87,063,050.57, showing stable operational management[13].